New research suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Research printed in a prominent medical journal shows that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these medications need to be aware of the danger of quick rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass within about one and a half years.
Analyzing Treatments
The analysis, which examined dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers emphasize that people who lose weight through diet and exercise generally experience a slower creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists suggest the mode of action of the injections explains the accelerated rebound.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to produce less of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Experiences
Individuals who have stopped the jabs describe a sudden resurgence of appetite.
"It was like something flipping and you become starving," recalled a patient.
This challenge is exacerbated if users have not established permanent lifestyle or habit changes during treatment.
Growing Adoption
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among women than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural support.
